Key Buffer Considerations for AAV Full Capsid Enrichment

Life Sciences, Pharma Manufacturing & Supply Chain, Drug Discovery & Development, Laboratory Technology, Cell and Gene Therapy,
  • Wednesday, November 02, 2022

Successful gene therapy using AAV vectors requires high titers of functional virus. A challenge in AAV production is the requirement for highly customized buffer formulations for each drug construct. In particular, thorough consideration of the buffers utilized is required in order to achieve full capsid enrichment in the final anion-exchange chromatography polishing step due to the unique capsid and transgene combination. In this webinar, the speaker will discuss the discreet, critical parameters that effect the downstream workflow for optimized AAV production.

Register for this webinar to learn about key buffer considerations for AAV full capsid enrichment.


Bella Neufeld, Teknova

Bella Neufeld, PhD, Director of Research and Development, Teknova

Bella Neufeld is the Director of Research and Development at Teknova, where she manages a gene therapy bioprocessing research program utilizing viral delivery systems. She joined Teknova’s Quality organization in 2018 and expanded their scientific capacity by increasing their testing capabilities through instrumentation and new techniques.

As Scientific Director, Bella assembled Teknova’s first internal R&D team when she led the rapid development of a novel transport media for Covid-19 testing. She also oversaw the building of Teknova’s new, state-of-the-art research laboratory.

After graduating with a Bachelor of Science degree in Chemistry from Sonoma State University, she earned her PhD in Chemistry from Colorado State University (CSU) where she set up and maintained two bacterial and tissue culture laboratories for studying drug delivery systems, including solid substrate and nanoparticle platforms. Bella actively presents her latest findings at industry events and her research is regularly featured in industry journals and publications.

Message Presenter

Who Should Attend?


  • Process development and R&D scientists working in downstream processing of AAV


  • Scientists within viral vector manufacturing, gene therapy, downstream workflows, process development

What You Will Learn

Attendees will gain insights into:

  • Processes within AAV downstream production that require buffer optimization
  • Critical parameters that affect the full capsid enrichment step in AAV purification

Xtalks Partner


Teknova expedites breakthroughs in modern medicine by providing critical reagents for the production of molecular diagnostics, novel vaccines, and next-generation therapies. With a focus on quality, speed, and service, we manufacture custom solutions that are used at every stage of the product development workflow, from basic research to product commercialization.

To meet the special demands of custom manufacturing, we built our production facilities with flexibility in mind, allowing us to quickly adapt our production setup to satisfy unique requests. Our R&D team, which focuses on increasing efficiency in gene therapy bioproduction, works with customers to define their needs, offering expertise from experimental design to guidance on manufacturing of custom reagents. With over 25 years of formulation, dispense, and QC expertise, we are able to deliver custom research and GMP products with exceptionally fast turnaround times, in formats that allow seamless integration into customer-specific workflows.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account